Top

Published in:

Open Access 01-05-2014 | Poster presentation

hMENA splicing program impacts the clinical outcome of early stage lung cancer patients. How and why?

Authors: Paolo Visca, Sheila Spada, Francesca Di Modugno, Emilio Bria, Isabella Sperduti, Barbara Antoniani, Gabriele Alessandrini, Belinda Palermo, Vienna Ludovini, Lucio Crinò, Francesco Facciolo, Michele Milella, Marcella Mottolese, Paola Nisticò

Published in: Journal of Translational Medicine | Special Issue 1/2014

Excerpt

In lung cancer, reliable prognostic indicators of the risk of recurrence are still not available. Alternative splicing represents a potential biomarker of diagnosis, prognosis, invasiveness, and response to therapy in different tumors [1], including lung cancer [2]. …

Pal S, Gupta R, Davuluri RV: Alternative transcription and alternative splicing in cancer. Pharmacol Ther. 2012, 136 (3): 283-94. 10.1016/j.pharmthera.2012.08.005.CrossRefPubMed

Stallings-Mann ML, Waldmann J, Zhang Y, Miller E, Gauthier ML, Visscher DW, Downey GP, Radisky ES, Fields AP, Radisky DC: Matrix metalloproteinase induction of Rac1b, a key effector of lung cancer progression. Sci Transl Med. 2012, 4 (142): 142ra95-PubMedCentralPubMed

Di Modugno F, Bronzi G, Scanlan MJ, Del Bello D, Cascioli S, Venturo I, Botti C, Nicotra MR, Mottolese M, Natali PG, Santoni A, Jager E, Nisticò P: Human Mena protein, a serex-defined antigen overexpressed in breast cancer eliciting both humoral and CD8+ T-cell immune response. Int J Cancer. 2004, 109 (6): 909-18. 10.1002/ijc.20094.CrossRefPubMed

Di Modugno F, Iapicca P, Boudreau A, Mottolese M, Terrenato I, Perracchio L, Carstens RP, Santoni A, Bissell MJ, Nisticò P: Splicing program of human MENA produces a previously undescribed isoform associated with invasive, mesenchymal-like breast tumors. Proc Natl Acad Sci U S A. 2012, 109 (47): 19280-5. 10.1073/pnas.1214394109.PubMedCentralCrossRefPubMed

Fridman WH, Pagès F, Sautès-Fridman C, Galon J: The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012, 12 (4): 298-306. 10.1038/nrc3245.CrossRefPubMed

Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012, 12 (4): 252-64. 10.1038/nrc3239.CrossRefPubMed

Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012, 366 (26): 2455-65. 10.1056/NEJMoa1200694.PubMedCentralCrossRefPubMed

Title: hMENA splicing program impacts the clinical outcome of early stage lung cancer patients. How and why?
Authors: Paolo Visca
Sheila Spada
Francesca Di Modugno
Emilio Bria
Isabella Sperduti
Barbara Antoniani
Gabriele Alessandrini
Belinda Palermo
Vienna Ludovini
Lucio Crinò
Francesco Facciolo
Michele Milella
Marcella Mottolese
Paola Nisticò
Publication date: 01-05-2014
Publisher: BioMed Central
Published in: Journal of Translational Medicine / Issue Special Issue 1/2014
Electronic ISSN: 1479-5876
DOI: https://doi.org/10.1186/1479-5876-12-S1-P12

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

hMENA splicing program impacts the clinical outcome of early stage lung cancer patients. How and why?

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Special Issue 1/2014

Long-term response after electrochemotherapy in patients with relapsed or refractory cutaneous melanoma

Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results

Psychological features in lower risk melanoma: an analysis on 204 patients

Assessment of germline and somatic alterations in main candidate genes among patients with multiple primary melanoma

Revealing cancer initiating cells in metastatic melanomas by harnessing the host′s anti tumor humoral immune mechanisms

MISIPI study: Melanoma ImmunoScore evaluation in patients treated with IPIlimumab

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page